Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 2
1986 1
1987 1
1989 1
1990 1
1991 3
1992 3
1993 2
1994 2
1995 1
1996 3
1997 3
1998 6
1999 1
2000 6
2001 6
2002 6
2003 15
2004 6
2005 5
2006 6
2007 9
2008 10
2009 17
2010 12
2011 13
2012 16
2013 6
2014 5
2015 11
2016 14
2017 22
2018 20
2019 15
2020 12
2021 18
2022 9
2023 8
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

264 results

Results by year

Filters applied: . Clear all
Page 1
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
Kosiborod M, Lam CSP, Kohsaka S, Kim DJ, Karasik A, Shaw J, Tangri N, Goh SY, Thuresson M, Chen H, Surmont F, Hammar N, Fenici P; CVD-REAL Investigators and Study Group. Kosiborod M, et al. Among authors: hammar n. J Am Coll Cardiol. 2018 Jun 12;71(23):2628-2639. doi: 10.1016/j.jacc.2018.03.009. Epub 2018 Mar 11. J Am Coll Cardiol. 2018. PMID: 29540325 Free article. Clinical Trial.
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group*. Kosiborod M, et al. Among authors: hammar n. Circulation. 2017 Jul 18;136(3):249-259. doi: 10.1161/CIRCULATIONAHA.117.029190. Epub 2017 May 18. Circulation. 2017. PMID: 28522450 Free PMC article. Clinical Trial.
Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer.
Harris RJ, Cheung A, Ng JCF, Laddach R, Chenoweth AM, Crescioli S, Fittall M, Dominguez-Rodriguez D, Roberts J, Levi D, Liu F, Alberts E, Quist J, Santaolalla A, Pinder SE, Gillett C, Hammar N, Irshad S, Van Hemelrijck M, Dunn-Walters DK, Fraternali F, Spicer JF, Lacy KE, Tsoka S, Grigoriadis A, Tutt ANJ, Karagiannis SN. Harris RJ, et al. Among authors: hammar n. Cancer Res. 2021 Aug 15;81(16):4290-4304. doi: 10.1158/0008-5472.CAN-20-3773. Epub 2021 Jun 15. Cancer Res. 2021. PMID: 34224371 Free PMC article.
Cohort Profile: The AMORIS cohort.
Walldius G, Malmström H, Jungner I, de Faire U, Lambe M, Van Hemelrijck M, Hammar N. Walldius G, et al. Among authors: hammar n. Int J Epidemiol. 2017 Aug 1;46(4):1103-1103i. doi: 10.1093/ije/dyw333. Int J Epidemiol. 2017. PMID: 28158674 No abstract available.
Considerations when planning and conducting large global observational studies: Experience from the DISCOVER study of patients with type 2 diabetes.
Aarskog P, Cid-Ruzafa J, Chen H, Fenici P, Gutierrez LR, Hammar N, Medina J, Pascual E, Saraiva GL, Surmont F, Sweet S, Ji L, Khunti K, Cooper A. Aarskog P, et al. Among authors: hammar n. Prim Care Diabetes. 2023 Oct;17(5):411-419. doi: 10.1016/j.pcd.2023.07.002. Epub 2023 Aug 5. Prim Care Diabetes. 2023. PMID: 37544790 Free article. Review.
A latent class model for competing risks.
Rowley M, Garmo H, Van Hemelrijck M, Wulaningsih W, Grundmark B, Zethelius B, Hammar N, Walldius G, Inoue M, Holmberg L, Coolen ACC. Rowley M, et al. Among authors: hammar n. Stat Med. 2017 Jun 15;36(13):2100-2119. doi: 10.1002/sim.7246. Epub 2017 Feb 24. Stat Med. 2017. PMID: 28233395
264 results